Quantcast
Home > Quotes > ALRN

Aileron Therapeutics, Inc. Common Stock (ALRN) Quote & Summary Data

ALRN 
$2.25
*  
0.04
1.81%
Get ALRN Alerts
*Delayed - data as of Nov. 15, 2018 11:11 ET  -  Find a broker to begin trading ALRN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ALRN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.21 / $ 2.25
Today's High / Low
$ 2.25 / $ 1.95
Share Volume
9,418
50 Day Avg. Daily Volume
71,086
Previous Close
$ 2.21
52 Week High / Low
$ 12.70 / $ 1.75
Market Cap
33,184,069
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
9,418
50 Day Avg. Daily Volume:
71,086

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.13

Trading Range

The current last sale of $2.25 is 28.57% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.25 $ 12.70
 Low: $ 1.95 $ 1.75

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company that is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Our lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. ALRN-6924, which is currently being tested in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2. Our ongoing clinical trials of ALRN-6924 consist of a Phase 1 trial for the treatment of advanced solid tumors or lymphomas, a Phase 2a trial for the treatment of peripheral T-cell lymphoma, or PTCL, a Phase 1 trial for the treatment of acute myeloid leukemia, or AML, and advanced myelodysplastic syndrome, or MDS, as a monotherapy and a Phase 1b trial for the treatment of AML/MDS in combination with cytosine arabinoside, or Ara-C.  ... More ...  


Risk Grade

Where does ALRN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.11
Open Date:
Nov. 15, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x